October 7, 2022
Sumitomo Pharma said on October 6 that it will post an impairment loss of some 54 billion yen in the second quarter of FY2022 due to sluggish sales of Kynmobi (apomorphine), a Parkinson’s disease treatment sold in the US via...read more